Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(0.91) by 1.1 percent. This is a 13.92 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $1.57 million which missed the analyst consensus estimate of $1.90 million by 17.21 percent. This is a 55.60 percent decrease over sales of $3.54 million the same period last year.